- $9.84m
- -$23.90m
- $4.50m
- 40
- 48
- 80
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.54 | ||
| Price to Tang. Book | 0.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.45% | ||
| Return on Equity | -61.34% | ||
| Operating Margin | -400.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.53 | 3.65 | 5.26 | 5.64 | 4.5 | 4.3 | n/a | -30.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
Directors
- Carolyn Egbert NEC
- Klaus Paulini PRE
- Giuliano La Fratta CFO
- Eckhard Gunther SVP
- Nicola Ammer SVP
- Guenther Grau VFN
- Matthias Gerlach VPR
- Dennis Turpin DRC
- Pierre-Yves Desbiens IND
- Peter Edwards IND (57)
- Gilles Gagnon IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 12th, 1990
- Public Since
- December 19th, 1995
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,855,876
- Address
- 315 Sigma Drive, SUMMERVILLE, 29486
- Web
- https://www.zentaris.com/
- Phone
- +1 4186528525
- Auditors
- Deloitte LLP
Upcoming Events for AEZS
Aeterna Zentaris Inc Annual Shareholders Meeting
Q2 2024 Aeterna Zentaris Inc Earnings Release
Similar to AEZS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the AEterna Zentaris share price?
As of Today at 19:00 UTC, shares in AEterna Zentaris are trading at $1.98. This share price information is delayed by 15 minutes.
How has the AEterna Zentaris share price performed this year?
Shares in AEterna Zentaris last closed at $1.98 and the price had moved by -25.19% over the past 365 days. In terms of relative price strength the AEterna Zentaris share price has underperformed the S&P500 Index by -39.58% over the past year.
What are the analyst and broker recommendations for AEterna Zentaris?
The overall consensus recommendation for AEterna Zentaris is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the AEterna Zentaris dividend yield?
AEterna Zentaris does not currently pay a dividend.
Does AEterna Zentaris pay a dividend?
AEterna Zentaris does not currently pay a dividend.
When does AEterna Zentaris next pay dividends?
AEterna Zentaris does not currently pay a dividend.
How do I buy AEterna Zentaris shares?
To buy shares in AEterna Zentaris you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AEterna Zentaris?
As of the previous close price of $1.98, shares in AEterna Zentaris had a market capitalisation of $9.84m.
Where are AEterna Zentaris shares listed?
Here are the trading details for AEterna Zentaris:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AEZS
What kind of share is AEterna Zentaris?
Based on an overall assessment of its quality, value and momentum AEterna Zentaris is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AEterna Zentaris share price forecast for 2024?
The analyst consensus target price for shares in AEterna Zentaris is $15.00. That is 659.49% above the last closing price of $1.98.
Analysts covering AEterna Zentaris currently have a consensus Earnings Per Share (EPS) forecast of -$3.37 for the next financial year.
What is the trend in the AEterna Zentaris share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AEterna Zentaris. Over the past six months, its share price has underperformed the S&P500 Index by -4.75%.
As of the last closing price of $1.98, shares in AEterna Zentaris were trading -9.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AEterna Zentaris PE Ratio?
The AEterna Zentaris PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AEterna Zentaris?
AEterna Zentaris' management team is headed by:
- Carolyn Egbert - NEC
- Klaus Paulini - PRE
- Giuliano La Fratta - CFO
- Eckhard Gunther - SVP
- Nicola Ammer - SVP
- Guenther Grau - VFN
- Matthias Gerlach - VPR
- Dennis Turpin - DRC
- Pierre-Yves Desbiens - IND
- Peter Edwards - IND
- Gilles Gagnon - IND